News >

Rapid Sequencing May Alleviate Sequencing Challenges in mCRPC

Jessica Hergert
Published: Friday, Mar 20, 2020

In the investigator-initiated PRINT study, we gave different approved treatments in a rapid sequence rather than giving 1 drug at a time until the patient becomes resistant. Our hypothesis was that we could give short bursts of [doublet therapies] to eradicate the resistant clone.

We know that people were particularly concerned about radium-223 [and the increased risk of bone fractures]. Although we did not see that in our study, we've realized that adding bone-protecting agents like denosumab (Xgeva) and zoledronic acid should be routine when giving radium-223 or an AR-targeted agent. Certainly, if you use both together, the evidence is pretty clear that you need a bone protecting agent on board.
Liaw BC, Tsao C, Galsky MD, et al. Print: Prostate cancer intensive, non-cross reactive therapy for CRP-early observations of efficacy. J Clin Oncol. 2020;38(suppl 6; abstr 89). doi: 10.1200/JCO.2020.38.6_suppl.89

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication